anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study will assess for the first time the effects of 5-HTP on neural excitability utilizing a combination of neurophysiological and functional testing in subacute motor complete (AIS A/B), chronic motor complete (AIS A/B) and chronic incomplete (AIS C/D) SCI participants. To reduce peripheral side effects such as nausea, these supplements will be co-administered with carbidopa which inhibits the action of peripheral AADC, thereby ensuring that 5-HTP can effectively cross the blood brain barrier prior to being broken down. The neurophysiological outcomes will allow for the determination of the mechanistic actions of each pharmacological agent on different pathways/sites within the central nervous system in three different patient populations with varying degrees of lesion severity and will for the determination of whether increased Amino Acid Decarboxylase (AADC) expression and therefore the efficacy of this approach is correlated to lesion severity and/or chronicity. Importantly, the use of functional testing will allow for the determination of whether these often-reported neurophysiological changes translate to improvements in muscle activation patterns and kinematics during cycling.

The effects of 5-HTP will be assessed across three different participant groups: i) subacute (6 months-1 year) AIS A/B SCI individuals, ii) chronic (\>2 years post injury) AIS A/B SCI individuals and iii) chronic AIS C/D SCI individuals.. In a placebo-controlled, randomized crossover design, participants will receive i) 50 mg 5HTP combined with 50 mg carbidopa, ii) 100 mg 5-HTP combined with 50 mg carbidopa, iii) 50 mg carbidopa only or iv) placebo. Ten participants will be recruited in each group. Participants will visit the lab on four separate occasions, separated by at least 72 hours.
BACKGROUND: This purpose aims to investigate the usefulness of CD133, a stem cell marker, for the prognosis of colon polyps. This study aimed to assess the adenomatous polyps that have an essential role in the development of colorectal cancer. The risk of colorectal carcinogenesis can be reduced by polypectomy and close medical supervision of the patients with adenomatous polyps. The prominence of stem cells in carcinoma development is also a recognized verdict. It must be noted that stem cell evaluation in adenomatous polyps may provide information about carcinoma development.
METHOD: Previously pathologically assessed colorectal polyps in 60 males and 40 females at Azerbaijan Medical University were reevaluated at the Pathology Department under the Meram Medical Faculty. Hematoxylin-eosin stained preparations were examined, and cases with and without dysplasia were determined. The image analysis program re-examined the preparations, and the same image analysis system automatically counted CD133 positive stained cells in the unit area. At the end of the follow-up period after polypectomy, the cases of malignancy were detected.
RESULTS: The relationship between CD133 expression of dysplasia and malignancy was statistically compared. During the investigation, the statistically significant relationship between CD133 expression and dysplasia, as well as malignancy development, was observed in this study.
CONCLUSION: During the examination, the statistical significance of CD133 expression was detected in cases with dysplasia and malignancy. The investigation of CD133 expression in colorectal polyps is crucial in determining the presence of dysplasia and malignancy development, particularly in obtaining prognostic data in colorectal polyps.
PURPOSE: To obtain a multiple unit preparation of medicine for oral administration affording zero-order diffusion-controlled release rate by providing a medicinally active substance-contg. core with a coating of film-forming polymer containing water-soluble fine hole-forming substance. CONSTITUTION: First, a coating liquid is prepared by dissolving in a solvent a polymer insoluble to, impermeable for and nonswellable for water and gastrointestinal juice (e.g. cellulose derivative, acrylic polymer) followed by mixing the resultant solution with a suspension of a water-soluble fine hole-forming substance (e.g. sucrose, sodium chloride). Subsequently, a core containing an active substance in the form of crystal or pellet is coated with the above coating liquid followed by drying to effect evaporation of the solvent, thus obtaining the objective polymer-coated multiple unit with the coating incorporated with the randomly distributed water-soluble fine hole-forming substance.
PROBLEM TO BE SOLVED: To obtain a wholly uniform liquid cosmetic excellent in effect effectively brightening only pores, acne mark, etc., and making unnoticeable and having natural finishing by attaching a globular complex powder having a specific composition to pores and acne mark. SOLUTION: This liquid cosmetic is obtained by dispersing titanium oxide or zinc oxide powder into the interior of base material particles of globular complex powder and using globular complex powder selected from resin and silicon oxide and supporting zirconium oxide or aluminum oxide thereon on the surface. The globular complex powder whose surface is further subjected to hydrophobic treatment is preferably used as the globular complex powder. The resin of the globular complex powder includes nylon resin, polyethylene resin, poly(methyl methacrylate) resin, polyester resin, polystyrene resin, polyurethane resin or silicone resin. The liquid cosmetic has preferably 1000-50000cps viscosity at 25 deg.C.  Powder of titanium oxide, etc., is blended in an amount of 5-60wt.% based on the base material particles and aluminum oxide, etc., is blended in an amount of 0.05-20wt.% based on complex powder.
Up to 40% of HCC patients have normal AFP. Moreover, AFP can also be elevated in patients with cirrhosis or exacerbation of chronic hepatitis. Prospective studies evaluating the value of AFP in HCC surveillance have reported sensitivities of 39-64%, specificity of 76-91% and positive predictive values of 9 -32% 9-11.

Recently, a small handful of biomarkers were identified in the blood of 49 HCC patients by SELDI / MS proteomic analysis of their blood with specificity and sensitivity both at 90% 12, 13. These were truncated complement C3a, albumin, B2 microglobulin, and histidine-rich glycoprotein. In addition, insulin growth factor (IGF) and its binding protein have been shown to be novel biomarkers of HCC 14-17. A larger prospective study is necessary to validate these findings.

Other investigators have also used Surface-enhanced laser desorption / ionization time-of-flight mass spectrometry (SELDI) to study proteomics in HCC. Most of the studies included small numbers of patients and did not include independent test set or report on reproducibility most of the time. Thus, controversies continue on both the technology of SELDI and validation of the findings. Nevertheless, Ward et al reported that Kappa and Lumda immunoglobulin light chains were elevated by an average pf 50% in the serum of HCC patients (p \< 0.001, sensitivity 94%, specificity 86%) with Hepatitis C related cirrhosis 18. Schwegler et al reported that SELDI-TOF MS profiling of serum can distinguish chronic Hepatitis C from HCV- related HCC with a sensitivity of 61% and a specificity of 76%. Sensitivity and specificity can be improved with the addition of AFP, des-gamma carboxyprothrombin, and GP73 19. Other reports also indicated potential marker of heat-shock protein 27 20 and complement C3a 21. However, all studies lack prospective and longitudinal follow-up with multiple serum samples from same patient. Our trial is designed to test the changes of proteomic overtime to identify the earliest possible biomarkers for HCC.
Enzymatic composition consists of a complex of an enzyme and a polymer which is soluble in aqueous alkali, and has a linear or branched carbon chain carrying carboxyl groups distributed along its length, opt. together with opt. substd. hydrocarbyl groups, the carbon chain and/or the hydrocarbyl groups being opt. interrupted by hetero atoms, pref. O and the polymer having an average mol. wt. >=10,000. Used in detergent compositions, the enzymatic compositions have a high stability, so that a lower quantity can be used in the detergent compositions. The enzymatic compositions also have a good colour and odour. The polymer is pref. an acrylic acid/methacrylic acid copolymer, or an interpolymer of acrylic acid, methacrylic acid or maleic acid with monomers such as styrene, ethylene or methyl vinyl ether. The polymer is esp. a maleic acid/styrene copolymer contg. maleic acid units and styrene units in a molar ratio of 3:2 to 2:3. The average mol. wt. of the polymer is pref. >20,000. The enzyme is pref. a protease which may be mixed with other enzymes such as amylase and/or lipase. The enzymatic composition may be reacted with a metallic ion which is reactive towards the free carboxyl groups, such as Al, Fe, Cr, or Zr. The composition is prepd. by contacting an aqueous soln. of the enzyme with the dissolved polymer.
Patients will receive the best available standard of care. Dose of sovateltide (0.3 µg/kg) will be administered as an intravenous bolus over one minute every 3 hours on day 1, day 3, and day 6 post randomizations.
Macrophage metabolic plasticity is central to inflammatory programming, yet mechanisms of coordinating metabolic and inflammatory programs during infection are poorly defined. Here, we show that type I interferon (IFN) temporally guides metabolic control of inflammation during methicillin-resistant Staphylococcus aureus (MRSA) infection. We find that staggered Toll-like receptor and type I IFN signaling in macrophages permit a transient energetic state of combined oxidative phosphorylation (OXPHOS) and aerobic glycolysis followed by inducible nitric oxide synthase (iNOS)-mediated OXPHOS disruption. This disruption promotes type I IFN, suppressing other pro-inflammatory cytokines, notably interleukin-1β. Upon infection, iNOS expression peaks at 24 h, followed by lactate-driven Nos2 repression via histone lactylation. Type I IFN pre-conditioning prolongs infection-induced iNOS expression, amplifying type I IFN. Cutaneous MRSA infection in mice constitutively expressing epidermal type I IFN results in elevated iNOS levels, impaired wound healing, vasculopathy, and lung infection. Thus, kinetically regulated type I IFN signaling coordinates immunometabolic checkpoints that control infection-induced inflammation.
Disclosed in the present invention are a spleen-strengthening and kidney-tonifying traditional Chinese medicine composition and an application thereof. The composition comprises the following components in parts by weight: 15-25 parts of radix puerariae, 12-18 parts of radix salviae miltiorrhizae, 25-35 parts of rhizoma atractylodis macrocephalae, 25-35 parts of radix pseudostellariae, 12-18 parts of cortex phellodendri, 25-35 parts of radix astragali, 12-18 parts of rhizoma dioscoreae, 12-18 parts of radix angelicae sinensis, 12-18 parts of fructus ligustri lucidi, 12-18 parts of fructus corni, 3-7 parts of radix glycyrrhizae preparata, and 8-12 parts of pericarpium citri reticulatae. The present invention relates to a formula for treating diabetes mellitus from the spleen and stomach theory. The effects of strengthening spleen, benefiting lung, tonifying kidney, nourishing yin and generating body fluid are achieved. The traditional Chinese medicine composition is used for treating diabetes caused by deficiency of both qi and yin, including dry mouth and polydipsia, throat dryness and dry cough, etc. After taking the traditional Chinese medicine composition, patients suffering from diabetes, diabetic retinopathy, diabetic nephropathy and other complications have obvious curative effects.
A method and a system for integrating a Radiology Information System (RIS) and hospital electronic medical records system (EMRS) within picture archiving and communications systems (PACS) to promote learner based education includes steps and means for flagging an interesting patient case, being viewed in PACS, for follow-up on diagnoses. Submitting the flagged interesting patient case, wherein the EMRS is queried for diagnoses information for the interesting patient case. Requesting a report for the interesting patient case where at least one diagnoses is available. Requesting feedback on a patient case interpretation, wherein information from PACS workstation and EMRS is sent to consulting physicians for reviewing. Requesting a report generation from the reviewing. Identifying an abnormality in a patient case image using the PACS workstation. Providing information regarding the abnormality. Requesting a differential diagnoses, wherein the information and the differential diagnoses table (DDT) are used to produce the differential diagnoses. Receiving the differential diagnoses.
The invention provides a method for preparing an iodic liquid embolic agent capable of long-time self-developing. Water-soluble polyvinyl alcohol (PVA) is added with pyridine to be stirred and evaporated for removing the pyridine. Residual reactant is dehumidified and dissolved in dimethyl sulphoxide (DMSO) organic solvent and then is added with solution of iodic compound and dichloromethane and added with triethylamine; and an obtained iodic product (I-PVA) is poured into a mixture of butyl ether and acetone to be deposited and separated. The iodic product is washed in water, is dried and then is confected into the liquid embolic agent by the dimethyl sulphoxide or N-methyl-ketopyrrolidine organic solvent. The liquid embolic agent prepared by the invention is injectable and can develop under X-ray for a long time. When contacting with blood, the organic solvent diffuses fast for depositing and separating solid to take embolic effect. The embolic agent can be used for embolotherapy of cerebral arteriovenous malformation, tumour and other vascular disease.
AZD3293 will be administered as single dose of an oral solution in Part 1 and single and multiple doses of an oral solution in Part 2. The ascending doses are planned to be 15, 50 and 150 mg for young subjects in Part 1 and 15 and 50 mg for elderly subjects in Part 2. Before proceeding to next dose level, safety, tolerability and pharmacokinetic data from the previous cohort(s) will be evaluated by a Safety Review Committee. Part 2 will start after confirming safety and tolerability in Part 1.
Healthy control participants were included if they reported a NDI \< 8% and a NPRS =0. They were excluded if they reported neck pain during the last year, radiating symptoms in the shoulder or arm regions, or headache. Participants with a history of neck trauma or in treatment for spinal disorders or reporting pain during the manual assessment were excluded as well.
Post-streptococcal glomerulonephritis is a condition resulting from infection by group A beta-hemolytic streptococcus. The main mechanism involves the formation of immune complexes formed in the circulation or in situ on the glomerular basement membrane, which activates complement and causes various inflammatory processes. Cellular mechanisms have been reported in the induction of kidney damage represented by the infiltration of innate cells (neutrophils and monocyte/macrophages) and adaptive cells (CD4 + lymphocytes and CD8 + lymphocytes) of the immune system. These cells induce kidney damage through various mechanisms. It has been reported that nephritogenic antigens are capable of inducing inflammatory processes early, even before the formation of immune complexes. Usually, this disease progresses towards clinical and renal normalization; however, in a smaller number of patients, it evolves into chronicity and persistent kidney damage. Hypotheses have been proposed regarding the mechanisms underlying this progression to chronicity including failure to induce apoptosis and failure to phagocytose apoptotic cells, allowing these cells to undergo membrane permeabilization and release pro-inflammatory molecules into the environment, thereby perpetuating renal inflammation. Other mechanisms involved include persistent infection, genetic background of the host's complement system, tubulointerstitial changes, and pre-existing kidney damage due to old age and comorbidities.
All participating medical institutions performing metabolic and bariatric surgeries from Poland can register patients via online questionaries. The database will include all patients with full preoperative history regarding the status of comorbidities, maximum weight and BMI. Details regarding initial surgery will be collected: type of procedure, time of procedure, length of the procedure, technical aspects (type of anastomosis, location of the anastomosis, type and amount of staplers used, length of bypassed jejunum, type of gastric band), length of hospital stay, short-term complications. The outcomes of initial surgery will be noticed: %TWL, minimum weight and BMI, remission of comorbidities, improvement of comorbidities, reduction of pharmacological treatment. Long-term postoperative complications in example de novo reflux, stenosis of anastomosis, stricture of gastric pouch will be included in analysis. The cause of revisionary surgery will be analyzed. The secondary bariatric procedure will be analyzed in terms of time, type and its length. Detail information of technical aspects will be collected. The complications and outcomes of revisional surgery will be acquired from hospitals registers, as well as, informations received from clinical follow-up.
The goal of this study is to determine if aspirin (acetylsalicylic acid) alters emotional reactions to emotion evoking pictures as well as memory for them. Using a double-blind parallel arm study, participants will receive either placebo or a pain-relieving dose of aspirin (500mg). One hour later they will complete 30 minutes of tasks. This will include ratings of emotional pictures and memory for them. The paradigm is similar to previous experiments done in this lab using other cyclooxygenase inhibitors: ibuprofen and acetaminophen (Durso, Luttrell, \& Way, 2015; Psychological Science, https://doi.org/10.1177/0956797615570366). Risk taking on the Balloon Analogue Risk Task will also be assessed. Participants will be healthy young adult males at Ohio State University.
BACKGROUND: Altered metabolism plays a role in the pathophysiology of cardiac diseases, such as atrial fibrillation (AF) and heart failure (HF). We aimed to identify novel plasma metabolites and proteins associating with cardiac disease.
METHODS: Mendelian randomisation (MR) was used to assess the association of 174 metabolites measured in up to 86,507 participants with AF, HF, dilated cardiomyopathy (DCM), and non-ischemic cardiomyopathy (NICM). Subsequently, we sourced data on 1567 plasma proteins and performed cis MR to identify proteins affecting the identified metabolites as well as the cardiac diseases. Proteins were prioritised on cardiac expression and druggability, and mapped to biological pathways.
RESULTS: We identified 35 metabolites associating with cardiac disease. AF was affected by seventeen metabolites, HF by nineteen, DCM by four, and NCIM by taurine. HF was particularly enriched for phosphatidylcholines (p = 0.029) and DCM for acylcarnitines (p = 0.001). Metabolite involvement with AF was more uniform, spanning for example phosphatidylcholines, amino acids, and acylcarnitines. We identified 38 druggable proteins expressed in cardiac tissue, with a directionally concordant effect on metabolites and cardiac disease. We recapitulated known associations, for example between the drug target of digoxin (AT1B2), taurine and NICM risk. Additionally, we identified numerous novel findings, such as higher RET values associating with phosphatidylcholines and decreasing AF and HF. RET is targeted by drugs such as regorafenib which has known cardiotoxic side-effects. Pathway analysis implicated involvement of GDF15 signalling through RET, and ghrelin regulation of energy homeostasis in cardiac pathogenesis.
CONCLUSIONS: This study identified 35 plasma metabolites involved with cardiac diseases and linked these to 38 druggable proteins, providing actionable leads for drug development.
Preterm infants matching the inclusion criteria (listed elsewhere) will be enrolled in a cross- over trial of two modes of non-invasive respiratory support: nasal intermittent positive pressure ventilation (PC-NIV) and NAVA NIV (Sevo-n Neonatal Ventilator, GETINGE, Solna, Sweden). Parental consent will be collected prior to the study. A 20-minute registration of ventilator parameters during assistance on NAVA-NIV will allow calculating the mean PIP (peak inspiratory pressure), in order to compare the two modes at the same level of PIP. The ventilator settings other than PIP (i.e. FiO2 (fraction of inspired oxygen), PEEP (positive end-expiratory pressure), IT (inspiratory time), RR (respiratory rate), NAVA level) will be based on the setting optimized by the attending physicians prior to the study entry. FiO2 will be adjusted in order to maintain SpO2 88-93% in infants ≤ 32 weeks of postconceptional age, 90-95% in infants \> 32 weeks of postconceptional age. Infants will then receive a randomized sequence of 1-hour assistance by NAVA NIV and 1-hour assistance PC-NIV or vice-versa. Infants will receive respiratory support in a standardized supine position during the study period.

Two, high-resolution, small cameras will be placed in the infant's incubator to detect chest and abdominal movements, by means of two markers placed on the infant's chest and abdomen. Ventilators parameters (flow, pressure, volume, the electrical activity of the diaphragm), vital signs (SpO2, HR (heart rate), ABP( arterial blood pressure)), transcutaneous gases, changes in end-expiratory lung volume will be collected continuously. Episodes of apnea, bradycardia or desaturations and the number of interventions required by the nurses and the attending physicians during the study (e.g. adjustment of the interface, suctioning, interventions to provide comfort or optimize the respiratory support...) will be also collected during the study. Patients' comfort will be assessed at the end of each sequence by the attending nurse by means of the COMFORT scale. Lung mechanics will be measured at the end of each sequence by means of the Forced Oscillation Technique.

Data will be then analysed and compared offline.
To provide a technique that allows pathological work to be done efficiently.SOLUTION: A pathological work support system according to an embodiment of the present disclosure is a pathological work support system for supporting pathological diagnosis work, and includes an AR apparatus and a server device. The AR apparatus includes: a camera for imaging a real space; and a display unit for overlapping images in the real space and displaying the images. The server device controls the AR apparatus. At least one of the server device and the AR apparatus has a tag information acquisition unit, a sample information acquisition unit, and a sample information display unit. The tag information acquisition unit is in the vision of the camera and acquires, from the camera, tag information which is printed on a member used when a sample to be subjected to a pathological diagnosis is pre-treated. The sample information acquisition unit acquires sample information on the sample attached to the acquired tag information. The sample information display unit overlaps the sample information on the member with the tag information printed thereon for display in the display unit.SELECTED DRAWING: Figure 1